N-Desmethylclozapine (NDMC), or norclozapine, is a major active metabolite of the atypical antipsychotic drug clozapine.

[1][2] Unlike clozapine, it possesses intrinsic activity at the D2/D3 receptors, and acts as a weak partial agonist at these sites similarly to aripiprazole and bifeprunox.

[7] It was hypothesized that on account of its unique actions, NDMC might underlie the clinical superiority of clozapine over other antipsychotics.

However, clinical trials found NMDC itself ineffective in the treatment of schizophrenia.

[8][9] This may be because it possesses relatively low D2/D3 occupancy compared to the 5-HT2 receptor (<15% versus 64–79% at a dose of 10–60 mg/kg s.c. in animal studies).